LLY Stock Intrinsic Value – Eli Lilly Announces Launch of Weight Loss Drug Zepbound in U.S.
December 11, 2023
🌧️Trending News
Eli ($NYSE:LLY) Lilly and Company, a leading global pharmaceutical corporation, has announced the launch of its weight-loss drug Zepbound in the U.S. Zepbound is an anti-obesity drug designed to help individuals reach their desired weight goals. It works by targeting the body’s hunger receptors and reducing the craving for food. In clinical trials, the drug has been proven to be more effective than placebo in reducing body mass index (BMI) and waist circumference. This launch marks the first time that an Eli Lilly drug has been approved for weight loss in the United States. Zepbound is the latest addition to Eli Lilly’s portfolio of therapeutic drugs, which includes treatments for diabetes, cancer, Alzheimer’s disease, and more.
With this launch, Eli Lilly is hoping to provide an effective treatment option for individuals looking to manage their weight. The company is currently developing treatments for a wide range of diseases and is actively researching new technologies to improve patient outcomes. The launch of Zepbound in the U.S. is yet another example of Eli Lilly’s commitment to providing innovative solutions to improve public health.
Market Price
This is the most recent addition to their growing portfolio of weight loss solutions. The news caused the stock to open at $583.3 and close at $588.2, up by 0.4% from prior closing price of $585.7. This minor increase is likely due to the overwhelming response to this new drug, believed to be the most effective weight loss solution on the market.
It is expected that this new product will help Eli Lilly capitalize on the growing health and wellness industry. The company is committed to providing safe and effective solutions for those dealing with obesity-related health issues. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for LLY. More…
| Total Revenues | Net Income | Net Margin |
| 32.07k | 4.99k | 24.0% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for LLY. More…
| Operations | Investing | Financing |
| 5.71k | -4.67k | -1.19k |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for LLY. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 57.92k | 46.61k | 11.82 |
Key Ratios Snapshot
Some of the financial key ratios for LLY are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 11.4% | 15.8% | 20.5% |
| FCF Margin | ROE | ROA |
| -0.5% | 36.9% | 7.1% |
Analysis – LLY Stock Intrinsic Value
GoodWhale has conducted an extensive analysis of the wellbeing of ELI LILLY AND and has determined that the fair value of their stock is around $359.6. Our proprietary Valuation Line was used to come to this conclusion and with it we were able to take into account factors such as the company’s industry, financials, and its competitive landscape. Despite this, ELI LILLY AND’s stock is currently trading at $588.2, which is an overvaluation of 63.6%. As such, we recommend exercising caution when considering investing in this company. More…
Peers
The competition between Eli Lilly and Co and its competitors is intense. Biogen Inc, Pfizer Inc, and Merck & Co Inc are all major players in the pharmaceutical industry, and each company is striving to be the top dog. Eli Lilly and Co has a strong presence in the United States, but its competitors are not far behind.
– Biogen Inc ($NASDAQ:BIIB)
Biogen Inc is an American multinational biotechnology company. The company is headquartered in Cambridge, Massachusetts, and has offices in Weston, Massachusetts; Research Triangle Park, North Carolina; Zurich, Switzerland; Maidenhead, United Kingdom; and Tokyo, Japan. Biogen Inc researches, develops, and manufactures therapies for the treatment of neurological and neurodegenerative diseases. The company’s products include AVONEX, TYSABRI, and FAMPYRA.
– Pfizer Inc ($NYSE:PFE)
Pfizer Inc has a market cap of 244.98B as of 2022, a Return on Equity of 24.63%. The company focuses on the discovery, development, and manufacture of biopharmaceutical products. Its portfolio includes medicines and vaccines for a wide range of conditions and diseases, such as Alzheimer’s disease, arthritis, cancer, and diabetes.
– Merck & Co Inc ($NYSE:MRK)
Merck & Co., Inc., d.b.a. Merck Sharp & Dohme (MSD) outside the United States and Canada, is an American multinational pharmaceutical company and one of the largest pharmaceutical companies in the world. The company was established in 1891 as the United States subsidiary of the German company Merck, which was founded in 1668 by the Merck family. Merck & Co. was subsequently acquired by Schering-Plough in 2009, and then by Merck KGaA in 2014. The company is headquartered in Kenilworth, New Jersey, and employs approximately 70,000 people in more than 140 countries.
Merck’s market cap is 238.43B as of 2022. The company has a Return on Equity of 28.84%. Merck & Co. is a multinational pharmaceutical company that is one of the largest in the world. The company was established in 1891 and has been acquired by Schering-Plough in 2009, and then by Merck KGaA in 2014. Merck & Co. is headquartered in Kenilworth, New Jersey, and employs approximately 70,000 people in more than 140 countries.
Summary
Eli Lilly and Co. has recently announced the U.S. availability of their weight loss drug Zepbound. The drug is expected to be a boon for the company, as it targets obesity which is a widespread issue in the United States. Analysts have suggested that this could be a profitable venture for the company and may even help raise Eli Lilly and Co.’s stock in the long run. Investors are advised to keep an eye on developments with the drug and make a decision based on their individual risk profile.
